Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $1.3 million.

  • Phathom Pharmaceuticals' Gains from Sales and Divestitures rose 5143.34% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 5143.34%. This contributed to the annual value of $965881.0 for FY2024, which is 436.35% down from last year.
  • Phathom Pharmaceuticals' Gains from Sales and Divestitures amounted to $1.3 million in Q3 2025, which was up 5143.34% from $965245.0 recorded in Q2 2025.
  • Phathom Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $1.3 million during Q3 2025, with a 5-year trough of $102453.0 in Q4 2022.
  • Moreover, its 4-year median value for Gains from Sales and Divestitures was $468563.0 (2023), whereas its average is $627640.2.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first surged by 88576.91% in 2023, then tumbled by 436.35% in 2024.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Gains from Sales and Divestitures stood at $102453.0 in 2022, then soared by 885.77% to $1.0 million in 2023, then fell by 4.36% to $965881.0 in 2024, then surged by 36.25% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $965245.0 for Q2 2025, and $508568.0 during Q1 2025.